Balazs Dome

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1820734/publications.pdf

Version: 2024-02-01

96 papers	3,549 citations	136950 32 h-index	155660 55 g-index
97 all docs	97 docs citations	97 times ranked	6071 citing authors

#	Article	IF	Citations
1	Alternative Vascularization Mechanisms in Cancer. American Journal of Pathology, 2007, 170, 1-15.	3.8	347
2	SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers. Molecular Cancer, 2017, 16, 1.	19.2	196
3	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. Journal of Pathology, 2017, 241, 362-374.	4.5	162
4	Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis. Journal of Thoracic Oncology, 2010, 5, 1120-1129.	1.1	110
5	Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. Journal of Pathology, 2002, 197, 355-362.	4.5	109
6	Afatinib restrains K-RASâ€“driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	12.4	99
7	Cell migration or cytokinesis and proliferation? â€“ Revisiting the â€œgo or growâ€•hypothesis in cancer cells in vitro. Experimental Cell Research, 2013, 319, 3094-3103.	2.6	84
8	Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget, 2014, 5, 4426-4437.	1.8	81
9	ÂÂLUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation. Journal of Experimental Medicine, 2016, 213, 2671-2689.	8.5	79
10	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	30.7	75
11	Angiogenesis-dependent diseases and angiogenesis therapy. Pathology and Oncology Research, 2001, 7, 85-94.	1.9	74
12	Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncology, 2011, 47, 487-496.	1.5	73
13	Apelin inhibition prevents resistance and metastasis associated with antiâ€•angiogenic therapy. EMBO Molecular Medicine, 2019, 11, e9266.	6.9	72
14	Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics, 2017, 7, 400-412.	10.0	71
15	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 738-746.	1.1	70
16	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy. European Journal of Cancer, 2014, 50, 1819-1828.	2.8	68
17	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. British Journal of Cancer, 2015, 113, 963-969.	6.4	68
18	Current therapy of KRAS-mutant lung cancer. Cancer and Metastasis Reviews, 2020, 39, 1159-1177.	5.9	66

#	Article	IF	Citations
19	Molecular profiles of small cell lung cancer subtypes: Therapeutic implications. Molecular Therapy - Oncolytics, 2021, 20, 470-483.	4.4	64
20	KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Scientific Reports, 2017, 7, 39721.	3.3	62
21	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. Lancet Microbe, The, 2021, 2, e300-e310.	7.3	60
22	A New Mechanism for Pillar Formation during Tumor-Induced Intussusceptive Angiogenesis: Inverse Sprouting. American Journal of Pathology, 2011, 179, 1573-1585.	3.8	59
23	Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 763-772.	5.6	59
24	Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Critical Reviews in Oncology/Hematology, 2009, 69, 108-124.	4.4	58
25	JAKâ€“STAT inhibition impairs Kâ€RASâ€driven lung adenocarcinoma progression. International Journal of Cancer, 2019, 145, 3376-3388.	5.1	54
26	Mechanism of tumour vascularization in experimental lung metastases. Journal of Pathology, 2015, 235, 384-396.	4.5	53
27	High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma. Oncotarget, 2016, 7, 13388-13399.	1.8	50
28	A Novel Concept of Glomeruloid Body Formation in Experimental Cerebral Metastases. Journal of Neuropathology and Experimental Neurology, 2003, 62, 655-661.	1.7	39
29	Development of Arterial Blood Supply in Experimental Liver Metastases. American Journal of Pathology, 2009, 175, 835-843.	3.8	39
30	Lung cancer in never smokers. Future Oncology, 2011, 7, 1195-1211.	2.4	39
31	3D histopathology of human tumours by fast clearing and ultramicroscopy. Scientific Reports, 2020, 10, 17619.	3.3	39
32	Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis. Neuro-Oncology, 2017, 19, 1058-1067.	1.2	38
33	Lack of Angiogenesis in Experimental Brain Metastases. Journal of Neuropathology and Experimental Neurology, 2011, 70, 979-991.	1.7	37
34	FGF2 and EGF induce epithelialâ€“mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis, 2018, 39, 534-545.	2.8	32
35	Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth inÂvivo. Surgery, 2017, 161, 735-746.	1.9	31
36	The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. Journal of Molecular Medicine, 2019, 97, 231-242.	3.9	29

#	Article	IF	Citations
37	Recombinant Human Erythropoietin alpha Improves the Efficacy of Radiotherapy of a Human Tumor Xenograft, Affecting Tumor Cells and Microvessels. Strahlentherapie Und Onkologie, 2008, 184, 1-7.	2.0	28
38	Epigenetic downâ€regulation of integrin Î±7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma. Journal of Pathology, 2015, 237, 203-214.	4.5	28
39	PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. Clinical Lung Cancer, 2019, 20, 363-369.e2.	2.6	28
40	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers. Oncotarget, 2015, 6, 394-408.	1.8	27
41	Stromal Expression of Heat-Shock Protein 27 Is Associated with Worse Clinical Outcome in Patients with Colorectal Cancer Lung Metastases. PLoS ONE, 2015, 10, e0120724.	2.5	26
42	Expression patterns and prognostic relevance of subtypeâ€specific transcription factors in surgically resected smallâ€cell lung cancer: an international multicenter study. Journal of Pathology, 2022, 257, 674-686.	4.5	26
43	New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study. Lung Cancer, 2018, 126, 139-148.	2.0	25
44	Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo. Clinical Cancer Research, 2018, 24, 3729-3740.	7.0	24
45	Mechanisms of vascularization in murine models of primary and metastatic tumor growth. Chinese Journal of Cancer, 2016, 35, 19.	4.9	23
46	DNA methylation of microRNAâ€coding genes in nonâ€smallâ€cell lung cancer patients. Journal of Pathology, 2018, 245, 387-398.	4.5	23
47	Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. Clinical Cancer Research, 2020, 26, 3819-3830.	7.0	23
48	Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma. Acta OncolÃ³gica, 2019, 58, 1087-1094.	1.8	22
49	Erythropoietin in Cancer: An Update. Current Molecular Medicine, 2008, 8, 481-491.	1.3	21
50	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma â€“ A multi-institutional study. European Journal of Cancer, 2016, 63, 64-73.	2.8	21
51	Proteomic Workflows for High-Quality Quantitative Proteome and Post-Translational Modification Analysis of Clinically Relevant Samples from Formalin-Fixed Paraffin-Embedded Archives. Journal of Proteome Research, 2021, 20, 1027-1039.	3.7	20
52	Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. PLoS ONE, 2015, 10, e0117021.	2.5	19
53	A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. PLoS ONE, 2015, 10, e0123661.	2.5	19
54	Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery. Journal of Surgical Oncology, 2017, 116, 227-235.	1.7	19

#	Article	IF	Citations
55	KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy. Cancers, 2019, 11, 1514.	3.7	19
56	BARD1 serum autoantibodies for the detection of lung cancer. PLoS ONE, 2017, 12, e0182356.	2.5	18
57	Profiling the Protein Targets of Unmodified Bioâ€Active Molecules with Drug Affinity Responsive Target Stability and Liquid Chromatography/Tandem Mass Spectrometry. Proteomics, 2020, 20, e1900325.	2.2	18
58	Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. Molecular Cancer Therapeutics, 2016, 15, 2357-2369.	4.1	17
59	EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. Translational Lung Cancer Research, 2021, 10, 662-674.	2.8	17
60	Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. Translational Lung Cancer Research, 2021, 10, 1594-1607.	2.8	17
61	Erythropoietin Receptor Expression Is a Potential Prognostic Factor in Human Lung Adenocarcinoma. PLoS ONE, 2013, 8, e77459.	2.5	17
62	Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. BMC Cancer, 2018, 18, 542.	2.6	16
63	Intrathoracic solitary fibrous tumor â€“ an international multicenter study on clinical outcome and novel circulating biomarkers. Scientific Reports, 2017, 7, 12557.	3.3	15
64	HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line. Pathology and Oncology Research, 2020, 26, 2523-2535.	1.9	15
65	Massive Withdrawal Symptoms and Affective Vulnerability Are Associated with Variants of the CHRNA4 Gene in a Subgroup of Smokers. PLoS ONE, 2014, 9, e87141.	2.5	14
66	The landscape of small cell lung cancer metastases: Organ specificity and timing. Thoracic Cancer, 2021, 12, 914-923.	1.9	14
67	From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC). PLoS ONE, 2016, 11, e0144797.	2.5	14
68	Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. Histopathology, 2020, 77, 55-66.	2.9	13
69	Apelin promotes blood and lymph vessel formation and the growth of melanoma lung metastasis. Scientific Reports, 2021, 11, 5798.	3.3	13
70	Inhibition of the transcriptional repressor complex Bcl-6/BCoR induces endothelial sprouting but does not promote tumor growth. Oncotarget, 2017, 8, 552-564.	1.8	13
71	Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma. Scientific Reports, 2017, 7, 16456.	3.3	12
72	Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors. Scientific Reports, 2019, 9, 17359.	3.3	12

#	Article	IF	Citations
73	Lung transplantation in patients with incidental early stage lung cancerâ€"institutional experience of a high volume center. Clinical Transplantation, 2016, 30, 912-917.	1.6	11
74	Significance of Primary Tumor Location and Histology for Brain Metastasis Development and Peritumoral Brain Edema in Lung Cancer. Oncology, 2016, 91, 237-242.	1.9	10
75	Expression of FGFR1â€"4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity. Cells, 2019, 8, 1091.	4.1	10
76	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine, 2021, 13, .	12.4	10
77	Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program. European Radiology, 2022, 32, 4457-4467.	4.5	9
78	The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization. Journal of Pathology, 2017, 241, 441-447.	4.5	8
79	Proteomic analysis enables distinction of earlyâ€versus advancedâ€stage lung adenocarcinomas. Clinical and Translational Medicine, 2020, 10, e106.	4.0	7
80	Role of (myo)fibroblasts in the development of vascular and connective tissue structure of the C38 colorectal cancer in mice. Cancer Communications, 2018, 38, 1-11.	9.2	5
81	Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor. Pathology and Oncology Research, 2021, 27, 1609926.	1.9	5
82	The possible role of maternal bonding style and CHRNB2 gene polymorphisms in nicotine dependence and related depressive phenotype. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 59, 84-90.	4.8	4
83	Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). Lung Cancer, 2014, 86, 54-58.	2.0	3
84	Reshaping a multimode laser beam into a constructed Gaussian beam for generating a thin light sheet. Journal of Biophotonics, 2018, 11, e201700213.	2.3	3
85	Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC). Translational Oncology, 2019, 12, 1539-1548.	3.7	3
86	Lung Transplant Patients on Kilimanjaro. Transplantation Proceedings, 2019, 51, 1258-1262.	0.6	3
87	Longitudinal analysis of complete blood count parameters in advancedâ€stage lung cancer patients. Thoracic Cancer, 2020, 11, 3193-3204.	1.9	3
88	The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation. Translational Lung Cancer Research, 2021, 10, 675-684.	2.8	3
89	Clinical relevance of circulating activin A and follistatin in small cell lung cancer. Lung Cancer, 2021, 161, 128-135.	2.0	3
90	Donation After Cardiac Death, a Possibility to Expand the Donor Pool: Review and the Hungarian Experience. Transplantation Proceedings, 2019, 51, 1276-1280.	0.6	2

#	Article	IF	Citations
91	Multicellular contractility contributes to the emergence of mesothelioma nodules. Scientific Reports, 2020, 10, 20114.	3.3	2
92	Reply to Rare Versus Artifactual EGFR Mutations. Journal of Thoracic Oncology, 2015, 10, e80-e81.	1.1	1
93	Maternal bonding styles in smokers and non-smokers: a comparative study. Annals of General Psychiatry, 2016, 15, 32.	2.7	1
94	Differences in the Epidemiology of Rare EGFR Mutations in Different Populations. Journal of Thoracic Oncology, 2016, 11, e19-e20.	1.1	1
95	A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma. Memo - Magazine of European Medical Oncology, 2015, 8, 52-56.	0.5	0
96	Levels of plasma fibulin-3 and accuracy of identifying patients with malignant pleural mesothelioma.. Journal of Clinical Oncology, 2014, 32, e18543-e18543.	1.6	0